

## **SUPPLEMENTAL FIGURE LEGENDS**

### **Supplemental Figure 1. Changes in Mean Transvalvular Gradient Over Time.**

**A.** Changes in the mean transvalvular gradient post-TAVR in the entire study population.

**B.** Changes in mean transvalvular gradient post-TAVR, according to the presence of anticoagulation therapy at hospital discharge.

### **Supplemental Figure 2. Incidence of Valve Hemodynamic Deterioration, According to Anticoagulation Therapy.**

### **Supplemental Figure 3. Individual Changes in Transvalvular Gradients Over Time Among 19 Patients with Valve Hemodynamic Deterioration at 1-Year Follow-Up.**

### **Supplemental Figure 4. Kaplan-Meier Survival Curves Following TAVR, According to Valve Hemodynamic Deterioration.**

**A.** Global death.

**B.** Cardiovascular death.

**C.** Stroke.

## **SUPPLEMENTAL TABLES**

### **Supplemental Table 1. Variables included in the propensity analysis.**

<i>Variables</i>	<b>OR (95% CI)</b>	<b>P value</b>
Age	1.03 (1.01-1.04)	<0.001
Previous coronary artery disease	0.68 (0.56-0.82)	<0.001
COPD	1.11 (0.90-1.36)	0.346
Mean gradient (baseline)	0.98 (0.97-0.99)	<0.001
LVEF (baseline)	0.85 (0.69-1.05)	0.133
Prosthesis size	1.09 (0.86-1.37)	0.477
Approach	0.63 (0.49-0.81)	<0.001
Valve type	1.07 (0.87-1.32)	0.490

**Supplemental Table 2. Baseline and Procedural Characteristics of the Study Population, According to Anticoagulation/DAPT Therapy at Hospital Discharge**

<b>Anticoagulation/DAPT Therapy</b>			
	<b>DAPT n=1326</b>	<b>Anticoagulation n=707</b>	<b>P value</b>
Age (years)	80.9±7.2	81.7±6.4	0.018
Male sex	600 (45.5)	333 (47.5)	0.399
Body mass index (kg/m <sup>2</sup> )	27.3±5.1	27.1±5.2	0.494
Diabetes mellitus	404 (31.4)	205 (29.9)	0.539
Coronary artery disease	723 (55.0)	323 (46.0)	<0.001
COPD	347 (26.4)	206 (29.4)	0.143
Atrial Fibrillation	131(10)	573 (80.9)	<0.001
CKD (eGFR <60 ml/min)	887 (66.9)	496 (70.2)	0.135
STS	7.1±6.1	7.9±5.9	0.037
<b>Baseline echocardiogram</b>			
LVEF≥50%	958 (72.3)	483 (68.3)	0.065
Mean gradient (mm Hg)	48.7±16.1	45.2±15.1	<0.001
Aortic regurgitation			
None/Trace	799 (65.2)	406 (63.1)	
Mild	326 (26.6)	188 (29.2)	
Moderate	78 (6.4)	41 (6.4)	0.562
Severe	22 (1.8)	8 (1.2)	
<b>Procedural</b>			
Approach			
Transfemoral	1160 (87.5)	513 (77.9)	
Transapical/transaortic	166 (12.5)	146 (22.2)	<0.001
Prosthesis type			
Balloon expandable	526 (39.7)	346 (48.9)	
Cribier Edwards	37 (2.8)	22 (3.1)	
Sapien	179 (13.5)	129 (18.3)	
Sapien XT	252 (19.0)	176 (24.9)	
Sapien 3	58 (4.3)	19 (2.7)	
Self-expandable	800 (60.4)	361 (51.1)	
Corevalve	672 (50.7)	291(41.2)	<0.001*
Evolut R	65 (4.9)	40 (5.7)	
Portico	11 (0.8)	3 (0.4)	
DirectFlow	40 (3.0)	14 (1.9)	
Lotus	11 (0.8)	11 (1.6)	
Other	1 (0.1)	2 (0.3)	
Valve size			
≤23 mm	330 (24.9)	201 (28.4)	
>23 mm	996 (75.1)	506 (71.6)	0.089
<b>Discharge echocardiogram</b>			

LVEF $\geq$ 50%	1032 (77.8)	524 (74.1)	0.062
Mean gradient (mm Hg)	9.7 $\pm$ 4.5	9.4 $\pm$ 4.5	0.084
Aortic regurgitation			
None/Trace	1053 (80.1)	565 (81.2)	
Mild	240 (18.3)	117 (16.8)	0.487
Moderate	22 (1.7)	13 (1.9)	
Severe	0	1 (0.1)	
<b>Discharge medication</b>			
Aspirin	1326 (100)	391 (56.0)	<0.001
Clopidogrel	1326 (100)	226 (32.4)	<0.001
VHD	45 (3.4)	4 (0.6)	<0.001

---

CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; LVEF: Left Ventricular Ejection Fraction. VHD: Valve Hemodynamic Deterioration  
 \*vs. Balloon expandable